# Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

> **NCT04706793** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 42 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Etrasimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04706793
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-25
- **Primary completion:** 2022-08-03
- **Final completion:** 2022-08-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706793, "Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04706793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*